In 2012, a randomized control trial was published that a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with hypercholesterolemia [51], [52]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.